Literature DB >> 8257829

Regulation of natural killer function by nonlymphoid cells.

H Shau1, M D Roth, S H Golub.   

Abstract

Natural killer (NK) cells and interleukin-2 activated NK cells, termed lymphokine-activated killer (LAK) cells, can lyse tumor cells without restriction by the MHC complex. The cytotoxic activity of these cells is subject to regulation by nonlymphoid cells in vitro. Interaction of NK cells with red blood cells (RBC) increases NK cytotoxicity. Interaction with polymorphonuclear neutrophils (PMN) suppresses LAK development and also inhibits NK- and LAK-mediated cytotoxicity at the effector cell phase. Exposure to tumor necrosis factor-alpha greatly enhances the inhibitory effect of PMN at the effector cell phase. Depending on their states of activation and differentiation, monocytes have the capacity to either enhance or suppress LAK induction. In contrast, macrophages derived from the lung are potent inhibitors of NK and LAK activity at both the induction and effector cell phases. Several cytokines are secreted by monocytes and macrophages and these include both suppressive and enhansive factors of cytotoxic function. Platelets are also capable of releasing suppressive factors. NK cells are believed to be involved in host surveillance of tumors, control of microbial infections and regulation of hematopoiesis. Regulation of NK cells by nonlymphoid cells and their products likely provides an in vivo mechanism for locally regulating NK function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257829

Source DB:  PubMed          Journal:  Nat Immun        ISSN: 1018-8916


  8 in total

1.  Role of von Willebrand factor in tumour cell-induced platelet aggregation: differential regulation by NO and prostacyclin.

Authors:  P Jurasz; M W Stewart; A Radomski; F Khadour; M Duszyk; M W Radomski
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  Immune cells in experimental acute kidney injury.

Authors:  Hye Ryoun Jang; Hamid Rabb
Journal:  Nat Rev Nephrol       Date:  2014-10-21       Impact factor: 28.314

Review 3.  Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation.

Authors:  Paul Jurasz; David Alonso-Escolano; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2004-10-18       Impact factor: 8.739

4.  Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines.

Authors:  E Heinmöller; R J Weinel; H H Heidtmann; U Salge; R Seitz; I Schmitz; K M Müller; H Zirngibl
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 5.  Metastasis review: from bench to bedside.

Authors:  Ali Mohammad Alizadeh; Sadaf Shiri; Sadaf Farsinejad
Journal:  Tumour Biol       Date:  2014-08-08

Review 6.  Cancer and Thrombosis: The Platelet Perspective.

Authors:  Claire K S Meikle; Clare A Kelly; Priyanka Garg; Leah M Wuescher; Ramadan A Ali; Randall G Worth
Journal:  Front Cell Dev Biol       Date:  2017-01-05

Review 7.  Fish Peroxiredoxins and Their Role in Immunity.

Authors:  Yulema Valero; Francisco J Martínez-Morcillo; M Ángeles Esteban; Elena Chaves-Pozo; Alberto Cuesta
Journal:  Biology (Basel)       Date:  2015-11-27

8.  SASP-Dependent Interactions between Senescent Cells and Platelets Modulate Migration and Invasion of Cancer Cells.

Authors:  Claudio A Valenzuela; Ricardo Quintanilla; Alexandra Olate-Briones; Whitney Venturini; Daniel Mancilla; Angel Cayo; Rodrigo Moore-Carrasco; Nelson E Brown
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.